S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:ARDX

Ardelyx Stock Forecast, Price & News

$1.52
-0.18 (-10.59%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.46
$1.92
50-Day Range
$0.86
$1.70
52-Week Range
$0.82
$2.31
Volume
145.72 million shs
Average Volume
10.27 million shs
Market Capitalization
$171.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.75
30 days | 90 days | 365 days | Advanced Chart
Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.


Ardelyx logo

About Ardelyx

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Headlines

Ardelyx, Inc. (NASDAQ:ARDX) Short Interest Down 23.4% in November
December 3, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
129
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.57 million
Book Value
$1.40 per share

Profitability

Net Income
$-94.31 million
Net Margins
-1,386.48%
Pretax Margin
-1,386.42%

Debt

Price-To-Earnings

Miscellaneous

Free Float
106,035,000
Market Cap
$171.37 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/14/2022

MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

366th out of 1,390 stocks

Pharmaceutical Preparations Industry

161st out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx
or view top-rated stocks.

How has Ardelyx's stock price been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARDX shares have decreased by 74.6% and is now trading at $1.52.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Ardelyx?

Ardelyx saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 5,890,000 shares, a drop of 23.4% from the October 31st total of 7,690,000 shares. Based on an average trading volume of 3,370,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 6.5% of the company's shares are short sold.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Ardelyx
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.07. Ardelyx had a negative trailing twelve-month return on equity of 132.31% and a negative net margin of 1,386.48%.
View Ardelyx's earnings history
.

What price target have analysts set for ARDX?

8 Wall Street analysts have issued 1-year price targets for Ardelyx's shares. Their forecasts range from $2.00 to $14.00. On average, they anticipate Ardelyx's share price to reach $7.09 in the next year. This suggests a possible upside of 366.3% from the stock's current price.
View analysts' price targets for Ardelyx
or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:

What other stocks do shareholders of Ardelyx own?

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.26%), Morgan Stanley (2.21%), Geode Capital Management LLC (1.71%), Pekin Hardy Strauss Inc. (1.23%), Congress Asset Management Co. MA (0.93%) and Millennium Management LLC (0.88%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx
.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Dimensional Fund Advisors LP, Citigroup Inc., Voya Investment Management LLC, Millennium Management LLC, Personal CFO Solutions LLC, California State Teachers Retirement System, and Alliancebernstein L.P.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, and Michael Raab.
View insider buying and selling activity for Ardelyx
or view top insider-selling stocks.

Which institutional investors are buying Ardelyx stock?

ARDX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Congress Asset Management Co. MA, Point72 Asset Management L.P., Geode Capital Management LLC, BlackRock Inc., Pekin Hardy Strauss Inc., and Goldman Sachs Group Inc..
View insider buying and selling activity for Ardelyx
or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $1.52.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $171.37 million and generates $7.57 million in revenue each year. The biopharmaceutical company earns $-94.31 million in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 129 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

Where are Ardelyx's headquarters?

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at [email protected], or via fax at 510-745-0493.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.